Metagenomi, Inc. Stock

Equities

MGX

US59102M1045

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 02:15:29 2024-05-03 pm EDT 5-day change 1st Jan Change
6.275 USD +1.70% Intraday chart for Metagenomi, Inc. -17.40% 0.00%
Sales 2024 * 32.37M Sales 2025 * 39.18M Capitalization 231M
Net income 2024 * -101M Net income 2025 * -119M EV / Sales 2024 * 7.14 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 5.9 x
P/E ratio 2024 *
-2.27 x
P/E ratio 2025 *
-2.23 x
Employees 236
Yield 2024 *
-
Yield 2025 *
-
Free-Float 66.51%
More Fundamentals * Assessed data
Dynamic Chart
1 day-12.36%
1 week-8.46%
Current month-12.11%
1 month-39.86%
More quotes
1 week
5.50
Extreme 5.5
8.40
1 month
5.50
Extreme 5.5
10.94
Current year
5.50
Extreme 5.5
12.74
1 year
5.50
Extreme 5.5
12.74
3 years
5.50
Extreme 5.5
12.74
5 years
5.50
Extreme 5.5
12.74
10 years
5.50
Extreme 5.5
12.74
More quotes
Date Price Change Volume
24-05-03 6.22 +0.81% 48 920
24-05-02 6.17 -12.36% 982,122
24-05-01 7.04 +0.28% 88,953
24-04-30 7.02 -13.33% 86,790
24-04-29 8.1 +7.57% 125,994

Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT

More quotes
Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed an expansive and modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. Its platform enables it to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicine.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
6.17 USD
Average target price
22.5 USD
Spread / Average Target
+264.67%
Consensus